• Nightingale Health signed a USD 1 million proteomics service agreement with medical research organization LifeArc for neurodegenerative disease research.
• The contract covers analysis of 10,000 UK Biobank samples using Alamar Biosciences' NULISAseq Neuro 220 Panel.
• It expands a USD 6.5 million agreement announced September 30, 2026, covering 60,000 UK Biobank samples using the same panel.
• The resulting protein biomarker data will be available to the wider research community through UK Biobank in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nightingale Health Oyj published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.